IRIX supply chain intelligence for IRIDEX Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
IRIDEX Corporation (IRIX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SFIII-FOS-HELLYER-HOLDING-LLC | SFIII-FOS-HELLYER-HOLDING-LLC | 92% | The Company and SFIII Hellyer, LLC and SFIII FOS Hellyer Holding, LLC (the “Landlord”) entered into a triple net lease |
| SFIII-HELLYER-LLC | SFIII-HELLYER-LLC | 92% | The Company and SFIII Hellyer, LLC and SFIII FOS Hellyer Holding, LLC (the “Landlord”) entered into a triple net lease |
| BHC | Bausch Health Companies Inc. | 72% | Reciprocal relationship from BHC graph: Reciprocal relationship from IRIX graph: ete by providing features and services that are valued by our customers such as: enhanced product performance and clin… |
| BHC | Bausch Health Companies Inc. | 72% | ete by providing features and services that are valued by our customers such as: enhanced product performance and clinical outcomes, ease of use, durability, versatility, customer training services a… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from IRIX graph: ete by providing features and services that are valued by our customers such as: enhanced product performance and cl… |
| NVSEF | Novartis AG | 72% | ete by providing features and services that are valued by our customers such as: enhanced product performance and clinical outcomes, ease of use, durability, versatility, customer training services a… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from IRIX graph: ete by providing features and services that are valued by our customers such as: enhanced product performance and cli… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ete by providing features and services that are valued by our customers such as: enhanced product performance and clinical outcomes, ease of use, durability, versatility, customer training services a… |
| SBC | SBC Medical Group Holdings Incorporated | 72% | Reciprocal relationship from SBC graph: Reciprocal relationship from IRIX graph: Reciprocal relationship from SBC graph: eline of top-tier development opportunities. Upon selecting a new market, we t… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| USGOV-DEPARTMENT-OF-DEFENSE | USGOV-DEPARTMENT-OF-DEFENSE | 95% | USAspending awards from Department of Defense: $375,108 across 8 awards. SPE2D425F734Y 4569557913!DIODE 532NM LASER; SPE2D425F739M 4569575782!DIODE 577NM LASER WITH MP CAPABILITY; SPE2D426F6019 4570… |
| USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | 95% | USAspending awards from Department of Health and Human Services: $12,483 across 1 awards. 75H71125P00092 IRIDEX LASER REPAIR; OPS DIODE REPLACEMENT. | Qwen corrected direction: Explicit government co… |
| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | 95% | USAspending awards from Department of Veterans Affairs: $38,719 across 1 awards. 36C24624P0052 HAMPTON VAMC IRIDEX OPHTHALMIC LASER MAINTENANCE. BASE PLUS TWO. | Qwen corrected direction: Explicit go… |
| TOPCON | TOPCON | 92% | For the three months ended April 4, 2026 and March 29, 2025, one customer, Topcon, accounted for more than 10% of total revenues, representing 27% and 30%, respectively. |
| BHC | Bausch Health Companies Inc. | 72% | Reciprocal relationship from BHC graph: Reciprocal relationship from IRIX graph: ete by providing features and services that are valued by our customers such as: enhanced product performance and clin… |
| BHC | Bausch Health Companies Inc. | 72% | ete by providing features and services that are valued by our customers such as: enhanced product performance and clinical outcomes, ease of use, durability, versatility, customer training services a… |
| NVSEF | Novartis AG | 72% | ete by providing features and services that are valued by our customers such as: enhanced product performance and clinical outcomes, ease of use, durability, versatility, customer training services a… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from IRIX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from IRIX graph: ete by providing features and ser… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from IRIX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from IRIX graph: Reciprocal relationship from REGN g… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ete by providing features and services that are valued by our customers such as: enhanced product performance and clinical outcomes, ease of use, durability, versatility, customer training services a… |
| LIQUIDITY-CAPITAL-RESOURCES | LIQUIDITY-CAPITAL-RESOURCES | 62% | $ 3,181 $ 462 14.5 % Retina 5,827 6,645 (818 ) (12.3 %) Other 2,329 2,070 259 12.5 % Total revenues $ 11,799 $ 11,896 $ (97 ) (0.8 %) 23 Our total revenues decreased by $0.1 million, or 0.8%, from $1… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IRIX-DEBT | Debt stack $3.2M | 90% | Market cache reports total debt of $3.2M. |
| IRIX-DEBT-10361 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2026-01-03. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IRIX-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 25 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BHC | Bausch Health Companies Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| NVSEF | Novartis AG | 100.00 | 1 | ['customer', 'supplier'] |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| INMD | InMode Ltd. | 100.00 | 2 | |
| MRM | MEDIROM Healthcare Technologies Inc. | 100.00 | 2 | |
| TOPCON | TOPCON | 63.48 | 1 | ['receiving'] |
| EDSA | Edesa Biotech, Inc. | 50.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 50.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 50.00 | 2 | |
| CPMV | Mosaic ImmunoEngineering, Inc. | 50.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 50.00 | 2 | |
| RGNX | REGENXBIO Inc. | 50.00 | 2 | |
| FATE | Fate Therapeutics, Inc. | 50.00 | 2 | |
| SDGR | Schrödinger, Inc. | 50.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 50.00 | 2 | |
| CRNX | Crinetics Pharmaceuticals, Inc. | 50.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 50.00 | 2 | |
| ALC | Alcon Inc. | 50.00 | 2 | |
| ALLR | Allarity Therapeutics, Inc. | 50.00 | 2 | |
| SLGL | Sol-Gel Technologies Ltd. | 50.00 | 2 |